5.3 Solid lipid nanoparticles for passive targeting

in liver weight with simultaneous reduction of serum alanine transaminase and liver triglyceride level. Biodistribution study reported 20-fold increase in the concentration of drug in the liver than that of blood. Moreover, it reduced the accumulation of fat and lipid droplet size. It was also noticed that the expression of lipogenic genes was down-regulated and lipolytic gene was up-regulated in BBR-SLNs treated

Cisplatin (CSPT) is an anti-cancer drug which is used in the treatment of many malignancies including hepatocellular carcinoma, lungs carcinoma, etc. The CSPT loaded SLNs (CSPT-SLNs) were successfully developed and were stable in terms of drug content after storage for 3 months in different temperature and humid conditions. In vivo tissue distribution study revealed that the developed CSPT-SLNs were able to deliver a higher amount of CSPT particularly to the liver as compared to the

Sorafenib (SFB), a potent multi-kinase inhibitor possess anti-tumor angiogenesis

effect (block vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGFR)) and is preferentially used in the treatment of hepatocellular carcinoma. The SFB loaded SLNs (SFB-SLNs) were developed with an objective of improving bioavailability and reducing adverse effects. The results of the stability test showed that SRF-SLNs remained stable for more than 1 month at room temperature. In vivo study of SFB-SLNs revealed improved bioavailability (increased by 66.7%) with remarkably higher bioaccumulation of drug in the liver (2.20-fold higher drug selectivity index value) when compared with the SFB

Primaquine phosphate (PP) is an antimalarial drug that acts on the primary tissue forms of the Plasmodium which after growth within the liver, initiate the erythrocytic stage. Thus, PP loaded SLNs (PP-SLNs) were developed with an aim to deliver liver schizonticide PP directly to the hepatocytes. Stability of the PP-SLNs in suspension was tested for a period of 3 months in terms of size, poly-dispersity, ζ-potential, and pH. There were no noteworthy changes in size, poly-dispersity, ζ-potential, or pH occurred over time. In vivo study report revealed that the developed SLNs were highly effective (>20%) against hypnozoites/liver stage of all malarial species with a reduced dose when compared with the conventional

The fibrous scars occurring in the liver due to the increased production and deposition of hepatic extracellular matrix (ECM) components are called liver fibrosis reduce the physiological performance of the liver. Hepatitis viral infection is one of the major reasons for liver fibrosis and cirrhosis. Administration of antifibrotic therapeutics (e.g. connective tissue growth factor (siRNA) responsible for the cellular and molecular basis of fibrogenesis) is one of the most preferable approaches for the treatment of liver fibrosis. The siRNA loaded cationic SLNs (cSLNs) were developed by gently mixing CSLNs with siRNA at various weight ratios of cSLN to siRNA in 0.1 M PBS (pH 7.4) and then incubated at room temperature for 15 min. Naturally obtained low-density lipids (LDLs) were used in the preparation. The developed cSLN were able to silence the targeted gene in the presence of serum with notably low cytotoxicity. The cSLNs were PEGylated which were hydrodynamically stable and were able to protect their siRNA cargo from nuclease degradation during systemic circulation. The developed cSLNs loaded with siRNA administer through intravenous route delivered siRNA exclusively to the liver and resulted in a considerable reduction in collagen content and pro-fibrogenic factors with spectacular progress of pathophysiological symptoms in a liver fibrosis rat

livers which could be helpful in the treatment of hepatosteatosis [46].

Role of Novel Drug Delivery Vehicles in Nanobiomedicine

brain, lungs, and kidney [47].

suspension [48].

oral dose [49].

106

5.2 Solid lipid nanoparticles delivering gene
